NCT06585449 · Phase 1 · RECRUITING
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
This trial is testing ALN-HTT02, an experimental drug designed to reduce the harmful huntingtin protein that drives Huntington's disease. Researchers are measuring safety, tolerability, and how the drug behaves in the body after single or repeated doses. It is a Phase 1 trial, meaning the primary goal is to establish that the drug is safe in humans — it is not yet proven or approved for any use.
Eligibility criteria
Inclusion Criteria * Has stage 2 or early Stage 3 Huntington's disease (HD), per the Huntington's Disease Integrated Staging System (HD-ISS) Exclusion Criteria * Has significant structural or degenerative neurologic disease other than Huntington's Disease (HD) at screening * Has primary or secondary immune compromise at screening due to infections, medical conditions, or chronic therapies * Has alanine aminotransferase or aspartate aminotransferase >2× upper limit of normal (ULN) * Has an estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73m\^2 at screening * Has received an investigational agent within the last 1 year or 5 half-lives (if known) Note: other protocol defined inclusion / exclusion criteria apply
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-31